Search clinical trials for: SBR759

Total 6 results

Novartis Pharmaceuticals

Completed

A Clinical Study to Evaluate the Safety, Tolerability and Activity of a New Phosphate Binder (SBR759) in Patients With Chronic Kidney Disease on Hemodialysis

Chronic Kidney Disease

United States
Novartis

Completed

Placebo Versus SBR759 in Lowering Phosphate in Dialysis Patients (SBR759)

Chronic Kidney Disease | Hyperphosphatemia

Belgium, Italy
Novartis Pharmaceuticals

Completed

Efficacy of SBR759 in Lowering Serum Phosphate Levels in Chronic Kidney Disease Patients on Hemodialysis (SBR759)

Hyperphosphatemia Patients With Chronic Kidney Disease on 3x/Week Replacement Therapy

Germany, United Kingdom, Italy, Belgium, Sweden, Canada, United States, Australia, Finland, France, Norway, Puerto Rico, Switzerland
Shanghai SIMR Biotechnology Co., Ltd.

Completed

The Pharmacokinetics (PK), Safety, Tolerability of SR750 in Healthy Volunteers

Healthy

China
Novartis Pharmaceuticals

Completed

Optimal Titration Regimen for SBR759 in Lowering Serum Phosphate Levels in Asian Chronic Kidney Disease Patients on Hemodialysis (SBR759)

Chronic Kidney Disease

Taiwan, Japan
SIMR (Australia) Biotech Pty Ltd.

Completed

The Safety, Tolerability, and Pharmacokinetics (PK) of SR750 in Healthy Volunteers

Healthy Volunteers

Australia

3

Subscribe